Acadia Pharmaceuticals (ACAD) Cash from Financing Activities (2010 - 2026)

Acadia Pharmaceuticals' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 130.2% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $52.3 million (up 584.24% YoY), while the FY2025 annual figure was $49.9 million, up 628.75% from the prior year.
• Cash from Financing Activities was $4.2 million for Q1 2026 at Acadia Pharmaceuticals, down from $22.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $22.7 million in Q4 2025 to a low of $268000.0 in Q3 2024.
• Historically, Cash from Financing Activities has averaged $5.5 million across 5 years, with a median of $3.6 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities surged 4342.86% in 2023, then slumped 97.9% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $1.6 million in 2022, then surged by 236.68% to $5.4 million in 2023, then sank by 63.77% to $2.0 million in 2024, then soared by 1051.14% to $22.7 million in 2025, then sank by 81.33% to $4.2 million in 2026.
• The last three Cash from Financing Activities figures came in at $4.2 million (Q1 2026), $22.7 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.